Research Group 1

A comprehensive study involving longitudinal analyses of cerebral images from healthy to pathological states by life stages (developmental, adulthood, and senile stages).

1-1

Identification of the pathogenic mechanism of mental and neurological disorders through acquisition and analysis of cerebral MRI-scan images and clinical data, etc.

The mechanism of brain development and disorders in adolescence and young adulthood (AYA) through international MRI collaborations

笠井 清登

Kiyoto KASAI

M.D., Ph.D., Professor, Graduate School of Medicine,
The University of Tokyo

The onset of many psychiatric disorders usually occurs in adolescents and young adults (AYA). The substrates of brain maturation in the AYA generation largely remain undiscovered. In our current research project, we will acquire longitudinal MRI data of patients with schizophrenia, those with developmental disorders, and typical developing individuals using the Human Connectome Project (HCP) protocol. In addition, we will share MRI data with our international collaborators. Through these approaches, we aim to elucidate mechanisms regarding the onset of psychiatric disorders in the AYA generation and to identify brain-circuit-based biomarkers that will be useful in diagnosis and predicting treatment outcomes.

国際MRI研究連携によるAYA世代脳発達および障害のメカニズム解明

Elucidation of neural circuits of mood disorder in adults and related disorders based on longitudinal MRI data

岡本 泰昌

Yasumasa OKAMOTO

M.D., Ph.D., Professor, Graduate School of Biomedical Medical Sciences, Hiroshima University

We obtain longitudinal MRI data and the associated clinical data targeting mood disorders (depression and bipolar disorders), anxiety disorders, obsessive-compulsive disorders, schizophrenia, subthreshold depression and healthy individuals in adulthood. By using this data and applying AI technology to the analyses, we propose a method to distinguish between bipolar disorder and depression, a method for predicting responses to treatment (clinical course) and biotypes based on the five diseases. We also contribute to the elucidation of the pathogenic mechanism by assessing MRI images showing changes from subthreshold depression to depression.

縦断的MRIデータに基づく成人期気分障害と関連疾患の神経回路の解明

Parkinson’s disease and Alzheimer’s disease Neuroimaging Initiative (PADNI) supported by MRI reference panels based on community-based cohort data

花川 隆

Takashi HANAKAWA

M.D., Ph.D., Director, Department of Advanced Neuroimaging, Integrative Brain Imaging Center, National Center of Neurology and Psychiatry

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common neurodegenerative disorders involving the elderly population. In this multi-center study, we aim to collect MRI data from participants with either AD or PD, “super-healthy” elderly people defined as being at risk of AD or PD, and intermediate states such as mild cognitive impairment (MCI). Simultaneously, we will develop an MRI reference panel representing the healthy elderly population derived from a mega-scale cohort study including 10,000 participants. By combining a cutting-edge MRI analysis of the multi-center data and the reference panel, we will clarify the similarities and differences of the neural circuits responsible for AD and PD.

先進的MRI技術に基づく統合データベースと大規模コホートデータの連結による高齢者神経変性疾患の責任神経回路の解明

Elucidation of the neural circuitry involved in symptomatic improvement and prognosis of psychiatric and neurological disorders resulting from therapeutic intervention

Association study of symptomatic efficacy of rasagiline with neurocircuits in Parkinson’s disease

服部 信孝

Nobutaka HATTORI

M.D., Ph.D., Professor, Department of Neurology, Juntendo University

The aim of this study is to accomplish Parkinson’s disease (PD) patient stratification analyzed by machine learning method based on the consecutive, comprehensive, and multi-layered data (cranial MRI including tensor imaging, plasma/serum metabolome, proteome, and miRNA transcriptome of the exosomes) taken from patients with PD treated with/without rasagiline, a potential disease-modifying drug for PD (N Engl J Med 2009, Lancet Neurol 2011). These neuroimaging markers in a data-driven approach would enable us to stratify patients with Parkinson’s disease into distinct clusters, leading to establish novel therapeutic strategies.

MAO-B阻害薬rasagilineによるパーキンソン病治療効果と神経回路変化についての研究

Longitudinal MRI study Identifying the Neural Substrates of Remission/Recovery in Mood Disorders (L/R Study)

三村 將

Masaru MIMURA

M.D., Ph.D., Department of Neuropsychiatry, School of Medicine, Keio University

Mood disorders are a leading cause of disability worldwide. However, despite the importance of understanding the etiology of mood disorders, there are still no established biological markers for their diagnosis and treatment.
First-line treatment strategies for depression, including pharmacotherapy and cognitive behavioral therapy (CBT), are effective only for two-thirds of patients, and the remaining one-third of patients are categorized as treatment-resistant depression (TRD). Repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT) are neuromodulation treatments for TRD. Psychiatrists usually provide these four treatments for individuals with mood disorders in daily clinical practice. However, it still remains unknown how each therapeutic intervention modulates neural circuits in the process of remission/recovery.
In the current study, we performed a large scale, multi-site, longitudinal magnetic resonance imaging (MRI) study to investigate the neural substrates of remission/recovery, and to identify a prediction model for treatment response/relapse in mood disorder patients.

気分障害における寛解と回復に関連した神経回路基盤の解明に資する縦断MRI研究

Generation of neuroscientific evidence of therapeutic intervention for psychiatric and neurological disorders

Study of optimization of epilepsy treatment using artificial intelligence

貴島 晴彦

Haruhiko KISHIMA

M.D., Ph.D., Professor, Graduate School of Medicine, Faculty of Medicine, Osaka University

The purpose of this project is to predict the prognosis of seizure suppression after the treatment in patients with epilepsy and to develop neuroscientific evidences to select the best treatment. First, from the Epilepsy Center of Osaka University Hospital and other several hospitals, physiological data, clinical data, before and after treatment, and prognostic data of epileptic patients during each life stage of children and adults are collected. Then we develop an artificial intelligence (AI) that is best suited for prognostic prediction from these data. In addition, based on the prediction with AI and biomarkers, we also establish the optimal treatment selection technology in the treatment of epilepsy.

人工知能を用いたてんかん治療の最適化に関する研究開発

Elucidation of neuroscientific evidence of the effects of cognitive behavioral therapy for eating disorders

関口 敦

Atsushi SEKIGUCHI

M.D., Ph.D., Section Chief, Department of Behavioral Medicine, National Center of Neurology and Psychiatry

Cognitive behavioral therapy (CBT) for eating disorders is a recommended treatment in Japan and overseas. However, the neuroscience mechanism of CBT effect on eating disorder is still unclear.
In this study, we will conduct a longitudinal observational study before and after CBT for eating disorders. We will collect brain MRI, psychological data, clinical data, etc. The aim of this research is to clarify the relationship between therapeutic effects and these data. Finally, we will create neuroscientific evidence of CBT effects that contribute to early detection and early intervention for eating disorder patients.
Specifically, we will identify diagnostic biomarkers of eating disorders by analyzing existing brain image databases of patients with eating disorders and healthy controls. Next, we will identify therapeutic biomarker as well as prediction biomarkers of treatment response of eating disorders by analyzing longitudinal MRI dataset before and after CBT.

摂食障害に対する認知行動療法の有効性の神経科学的エビデンスの創出

Elucidation of neural basis of pharmacotherapy for attention-deficit hyperactivity disorder

髙橋 英彦

Hidehiko TAKAHASHI

M.D., Ph.D., Professor, Department of Psychiatry and Behavioral Sciences, Graduate School of Medicine, Tokyo Medical and Dental University

In this study, we will conduct multimodal brain imaging in addition to the assessment of clinical symptoms, cognitive and behavioral signs before and after the initiation of methylphenidate (MPH) for individuals with attention deficit hyperactivity disorder. The purpose of this study is to identify the subtype of ADHD who are responders of MPH treatment, and to show the neuroscience evidence of the MPH effect by multimodal brain imaging.
Tokyo Medical and Dental University will exhibit coordination functions for patient recruitment and multimodal brain imaging. Neuropsychiatric Research Institute, Showa University, and National Institutes for Quantum and Radiological Science and Technology respectively will examine each modality of MRI, EEG and PET before and after MPH treatment.

注意欠如多動性障害の薬物療法の神経基盤の解明
1-2

Cerebral MRI-scan image data platform

Integrative MRI data platform across the lifespan and disorders toward international brain science collaborations

笠井 清登

Kiyoto KASAI

M.D., Ph.D., Professor, Graduate School of Medicine,
The University of Tokyo

Human brain imaging data has expanded in quality and quantity because of the progress of analysis methods and measurement techniques and the development of domestic and international collaborative studies. However, a framework has not been established to easily provide large datasets to researchers. In this study, we aim to develop a framework to manage and provide large-scale MRI datasets on healthy populations and neuropsychiatric disorders across life-span in Japan for promoting international collaborations.

人生ステージに沿った健常および精神・神経疾患の統合MRIデータベースの構築にもとづく国際脳科学連携